Research publications from Maverex
We share peer-reviewed research publications across oncology, cardiovascular, infectious disease and much more.
Browse or search our latest publications.
Health care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: a real-world observational retrospective cohort study
Samnaliev M, Barut V, Weir S, Langham J, Langham S, Wang X, Desta B, Hammond ER. THU0550 Health care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: a real-world observational retrospective cohort study. Ann Rheum Dis 2020;79(Suppl 1):515–6
Patient engagement process in rare disease: how does it differ between countries?
Skeldon G, Adkins E, Ayre S, Langham S, Nicholson L. PRO95 Patient engagement process in rare disease: how does it differ between countries? Value Health 2020;23(Suppl 2):S706
A review of exceptional circumstances marketing authorisations granted by the European Medicines Agency
Marjenberg Z, Teague R, Skeldon G. PMU50 A review of exceptional circumstances marketing authorisations granted by the European Medicines Agency. Value Health 2020;23(Suppl 2):S611
Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis
Yazdany J, Pooley N, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond E. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open 2020;6(2):e001247
The risk of venous thromboembolic events in adult patients with systemic lupus erythematosus: a systematic review and meta-analysis
Pooley N, Yazdany J, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond ER. The risk of venous thromboembolic events in adult patients with systemic lupus erythematosus: a systematic review and meta-analysis. Ann Rheum Dis 2019;78(Suppl 2):A804
The increasing use and acceptance of alternative statistical approaches to indirect comparison in the NICE HTA submission process
Pooley N, Marjenberg Z, Embleton N, Langham S. The increasing use and acceptance of alternative statistical approaches to indirect comparison in the National Institute of Health and Care Excellence (NICE) health technology assessment (HTA) submission process. Value Health 2019:22(Suppl 3):S814
Therapeutic benefit of orphan drugs in oncology: evidence at the point of European Marketing Authorisation
Odnoletkova I, Marjenberg Z, Pooley N, Langham S. Therapeutic benefit of orphan drugs in oncology: evidence at the point of European Marketing Authorisation. Value Health 2019;22(Suppl 3): S491
The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries
Nicholson L, Langham S, Adkins E. The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries. Value Health 2019:22(Suppl 3):S860
A systematic review of single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (COPD)
Langham S, Lewis J, Pooley N, Embleton N, Langham J. A systematic review of single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (COPD). Value Health 2019;22(Suppl 3):S873
